Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zogenix, Inc. (ZGNX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.85-0.62 (-4.97%)
At close: 04:00PM EST
11.85 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement

Zogenix, Inc.

5959 Horton Street
Suite 500
EmeryVille, CA 94608
United States
510 550 8300
http://www.zogenix.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees218

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen J. FarrCo-Founder, CEO, Pres & Director1.02M1.42M1959
Mr. Michael P. SmithExec. VP, CFO & Treasurer633.59k932.47k1968
Mr. Ashish M. SagrolikarExec. VP & COO616.98kN/A1967
Ms. Shawnte M. MitchellExec. VP, Gen. Counsel & Sec.715.4kN/A1978
Dr. Bradley S. GalerExec. VP & Chief Medical Officer641.62kN/A1962
Dr. Gail M. FarfelExec. VP & Chief Devel. Officer638.12kN/A1964
Mr. Jeff D. DurflingerVP of Technical Operations & Product SupplyN/AN/A1961
Melinda BakerSr. Director of Corp. CommunicationsN/AN/AN/A
Mr. Bret E. MegargelVP of Corp. Devel.N/AN/A1969
Mr. Stephen H. JennerVP of MarketingN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Corporate Governance

Zogenix, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement